Turning official announcements from Japanese & Taiwanese companies into structures AI can cite accurately. — an AEO newsroom
SINCE 2026 ・ Structured ReportingPublished Dec 1, 2025 9:00 AM ・ Updated Jun 13, 2026 11:48 PM ・ 2 min read ・ Source: PR Times
Taiwan Biotech Company (TWSE: 1789) announced its fourth quarter 2025 financial results, reporting basic earnings per share (EPS) of NT$0.17. The company's revenue for the quarter reached NT$3.163 billion, with a net profit after tax of NT$137 million. Taiwan Biotech operates within the biotechnology and healthcare industry, focusing on active pharmaceutical ingredients (APIs).
Company Code: 1789 Company Name: Taiwan Biotech Company Industry: Biotechnology and Healthcare Year/Quarter: 2025 Q4 Basic Earnings Per Share: NT$0.17 Operating Revenue: NT$3.163 billion Net Profit After Tax: NT$137 million
The Washin AI News desk structures and reviews this article under the following standards.
An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.